Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.

Cancer Med · 2023 · PMC10028028 · PMID 36250532

Europe PMC DOI

hedged sentence

0.2560

closest p · 5.1× alpha

0.2560

boldest claim

The sentences

did not reach statistical significancep = 0.256not close (p > 0.1)

However, the difference did not reach statistical significance ( p = 0.256).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.